BACKGROUND: Heat shock protein (Hsp) 90 is a key regulator of various oncogene products and cell-signaling molecules, while Hsp70 protects against heat-induced apoptosis. We previously described a system in which hyperthermia was produced using thermosensitive ferromagnetic particles (FMPs) with a Curie temperature (T c) of 43 °C to mediate automatic temperature control, and demonstrated its antitumor effect in a mouse melanoma model. In the present study, the antitumor effects of combining Hsp90 inhibitor (17DMAG) and Hsp70 inhibitor (quercetin) with FMP-mediated hyperthermia were examined. METHODS: Expressions of Hsp90/70 and Akt were evaluated using Western blotting in vitro. In an in vivo study, melanoma cells were subcutaneously injected into the backs of C57BL/6 mice. FMPs were then injected into the resultant tumors, and the mice were divided into groups treated with quercetin and/or 17DMAG with/without hyperthermia. When exposed to a magnetic field, the temperature of tissues containing FMPs increased and stabilized at the T c. The TUNEL method was used to determine whether hyperthermia induced apoptosis within tumors. RESULTS: In the group pretreated with hyperthermia + quercetin + 17DMAG, Akt expression was reduced in vitro, the incidence of apoptosis within tumors was greater, and tumor growth was significantly suppressed 20 days after FMP injection in vivo, compared with other treatment groups. The survival rates among tumor-bearing mice observed for a period of 40 days were significantly higher in the hyperthermia + quercetin + 17DMAG group. CONCLUSION: Combining Hsp90/70 inhibition with hyperthermia appears to increase their antitumor effects. Thus, the combination of FMP-mediated, self-regulating hyperthermia with Hsp90/70 inhibition has important implications for cancer treatment.
BACKGROUND:Heat shock protein (Hsp) 90 is a key regulator of various oncogene products and cell-signaling molecules, while Hsp70 protects against heat-induced apoptosis. We previously described a system in which hyperthermia was produced using thermosensitive ferromagnetic particles (FMPs) with a Curie temperature (T c) of 43 °C to mediate automatic temperature control, and demonstrated its antitumor effect in a mousemelanoma model. In the present study, the antitumor effects of combining Hsp90 inhibitor (17DMAG) and Hsp70 inhibitor (quercetin) with FMP-mediated hyperthermia were examined. METHODS: Expressions of Hsp90/70 and Akt were evaluated using Western blotting in vitro. In an in vivo study, melanoma cells were subcutaneously injected into the backs of C57BL/6 mice. FMPs were then injected into the resultant tumors, and the mice were divided into groups treated with quercetin and/or 17DMAG with/without hyperthermia. When exposed to a magnetic field, the temperature of tissues containing FMPs increased and stabilized at the T c. The TUNEL method was used to determine whether hyperthermia induced apoptosis within tumors. RESULTS: In the group pretreated with hyperthermia + quercetin + 17DMAG, Akt expression was reduced in vitro, the incidence of apoptosis within tumors was greater, and tumor growth was significantly suppressed 20 days after FMP injection in vivo, compared with other treatment groups. The survival rates among tumor-bearing mice observed for a period of 40 days were significantly higher in the hyperthermia + quercetin + 17DMAG group. CONCLUSION: Combining Hsp90/70 inhibition with hyperthermia appears to increase their antitumor effects. Thus, the combination of FMP-mediated, self-regulating hyperthermia with Hsp90/70 inhibition has important implications for cancer treatment.
Authors: Udai Banerji; Anne O'Donnell; Michelle Scurr; Simon Pacey; Sarah Stapleton; Yasmin Asad; Laura Simmons; Alison Maloney; Florence Raynaud; Maeli Campbell; Michael Walton; Sunil Lakhani; Stanley Kaye; Paul Workman; Ian Judson Journal: J Clin Oncol Date: 2005-06-20 Impact factor: 44.544
Authors: A Sittler; R Lurz; G Lueder; J Priller; H Lehrach; M K Hayer-Hartl; F U Hartl; E E Wanker Journal: Hum Mol Genet Date: 2001-06-01 Impact factor: 6.150
Authors: Victoria Smith; Edward A Sausville; Richard F Camalier; Heinz-Herbert Fiebig; Angelika M Burger Journal: Cancer Chemother Pharmacol Date: 2005-04-20 Impact factor: 3.333
Authors: Kheem S Bisht; C Matthew Bradbury; David Mattson; Aradhana Kaushal; Anastasia Sowers; Stephanie Markovina; Karen L Ortiz; Leah K Sieck; Jennifer S Isaacs; Martin W Brechbiel; James B Mitchell; Leonard M Neckers; David Gius Journal: Cancer Res Date: 2003-12-15 Impact factor: 12.701
Authors: M Abe; M Hiraoka; M Takahashi; S Egawa; C Matsuda; Y Onoyama; K Morita; M Kakehi; T Sugahara Journal: Cancer Date: 1986-10-15 Impact factor: 6.860
Authors: Lianne E M Vriend; Nathalie van den Tempel; Arlene L Oei; Mike L'Acosta; Frederique J Pieterson; Nicolaas A P Franken; Roland Kanaar; Przemek M Krawczyk Journal: Oncotarget Date: 2017-10-27